Form 4 for IDYA IDEAYA Biosciences, Inc.
Accepted 2023-08-11 00:00:00 ET · period of report 2023-08-09 · accession 0001610717-23-000226 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2023-08-11 | 2023-08-09 | IDYA | Throne Jason | CLO | S - Sale+OE | $25.09 | -5,000 | 0 | -100% | -$125.5K |
| DT | 2023-08-11 | 2023-08-09 | IDYA | Throne Jason | CLO | M - OptEx | $13.34 | +5,000 | 5,000 | New | +$66.7K |
| DT | 2023-08-11 | 2023-08-09 | IDYA | Throne Jason | CLO | M - OptEx | $0.00 | -5,000 | 57.6K | -8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-08-09 | S | D | 5,000 | $25.09 | 0 | D | — | — | (F2) This transaction was executed in multiple trades in prices ranging from $25.00 to $25.18, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2023-08-09 | M | A | 5,000 | $13.34 | 5,000 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2023-08-09 | M | D | 5,000 | $0.00 | 57,610 | D | $13.34 · — to 2030-06-30 | 5,000 Common Stock | (F3) 25% of the shares subject to the option vest on the first anniversary measured from July 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |